HDAC9 and ovarian serous adenocarcinoma: In non-serous ovarian cancer cells, HDAC9 decreases the acetylation of β-catenin K49 and induces β-catenin translocation to the cytoplasm, inactivating EMT and inhibiting cell migration and invasion [72].